Fahimeh Faqihi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hypoxic burden from obstructive sleep apnea is increased in Pacific Islanders with distinct pathophysiological traits

    by Fahimeh Faqihi, Christina Naidoo, Lucy Lawrence, Pamela Johnson, Stephen Lambert, Shane A Landry, Denise M O’DRiscoll, Bradley A Edwards, John R Wheatley, Kristina Kairaitis

    Study Objectives: Obstructive sleep apnea (OSA) is common in Pacific Islanders; however, its pathophysiological mechanisms are unknown. We compared OSA severity and endotypes between Pacific Islanders and Caucasians. Materials and Methods: Retrospective polysomnography data were analyzed using inverse probability of treatment weighting (IPTW) to balance age, sex, and BMI. Sleep stage endotypes were derived using validated non-invasive methods. Generalized linear models (GLMs) were used to estimate population-average differences and rank-based tests used as sensitivity analyses. Results: Forty two Pacific Islanders vs 62 Caucasians were included. There was no difference in apnea–hypopnea index between groups (adjusted mean difference 2.8 events/h, 95% CI [−9.0 to 14.5]; p = .64). Pacific Islanders had higher mean apnea length (5.6 s, [2.1 to 8.9]; p = .001), oxygen desaturation index ≥3% (12.5 events/h, [4.3 to 20.7]; p = .003), average desaturation during events (2.4%, [1.1 to 4.0]; p < .001), time with SpO₂ < 90% (12.3 min, [2.5 to 22.0]; p = .016), hypoxic burden (67.4% min/h, [21.7 to 113.2]; p = .012) and supine proportion (20.8% [6.6 to 34.9], pGLM = 0.005). They also had higher rapid eye movement (REM) arousal threshold (14.4%Veupnea, [1.3 to 27.5]; p = .033), lower REM Vpassive (−13.3%Veupnea, [−23.8 to −2.9]; p = .015), and higher non-rapid eye movement (NREM) loop gain (0.04, [0.00 to 0.09]; p = .047), except for REM arousal threshold endotype differences were absent after supine adjustment. Conclusions: In Pacific Islanders, OSA is characterized by longer apnea and increased hypoxic burden, with distinct endotypes. Strategies targeting endotypes and hypoxic burden may improve treatment and mitigate cardiometabolic consequences in this population.

  • Open Access

    A Simple Model to Study Mosaic Gene Expression in 3D Endothelial Spheroids

    by Lucinda S. McRobb, Vivienne S. Lee, Fahimeh Faqihi, Marcus A. Stoodley

    Aims: The goal of this study was to establish a simple model of 3D endothelial spheroids with mosaic gene expression using adeno-associated virus (AAV) transduction, with a future aim being to study the activity of post-zygotic mutations common to vascular malformations. Methods: In this study, 96-well U-bottom plates coated with a commercial repellent were seeded with two immortalized human endothelial cell lines and aggregation monitored using standard microscopy or live-cell analysis. The eGFP expression was used to monitor the AAV transduction. Results: HUVEC-TERT2 could not form spheroids spontaneously. The inclusion of collagen I in the growth medium could stimulate cell aggregation; however, these spheroids were not stable. In contrast, the hCMEC/D3 cells aggregated spontaneously and formed reproducible, robust 3D spheroids within 3 days, growing steadily for at least 4 weeks without the need for media refreshment. The hCMEC/D3 spheroids spontaneously developed a basement membrane, including collagen I, and expressed endothelial-specific CD31 at the spheroid surface. Serotypes AAV1 and AAV2QUADYF transduced these spheroids without toxicity and established sustained, mosaic eGFP expression. Conclusions: In the future, this simple approach to endothelial spheroid formation combined with live-cell imaging could be used to rapidly assess the 3D phenotypes and drug and radiation sensitivities arising from mosaic mutations common to brain vascular malformations.


  • Open Access

    The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations

    by Fahimeh Faqihi, Marcus A. Stoodley, Lucinda S. McRobb

    In cardiovascular and cerebrovascular biology, control of thrombosis and the coagulation cascade in ischemic stroke, myocardial infarction, and other coagulopathies is the focus of significant research around the world. Ischemic stroke remains one of the largest causes of death and disability in developed countries. Preventing thrombosis and protecting vessel patency is the primary goal. However, utilization of the body’s natural coagulation cascades as an approach for targeted destruction of abnormal, disease-associated vessels and tissues has been increasing over the last 30 years. This vascular targeting approach, often termed “vascular infarction”, describes the deliberate, targeted delivery of a thrombogenic effector to diseased blood vessels with the aim to induce localized activation of the coagulation cascade and stable thrombus formation, leading to vessel occlusion and ablation. As systemic delivery of pro-thrombotic agents may cause consternation amongst traditional stroke researchers, proponents of the approach must suitably establish both efficacy and safety to take this field forward. In this review, we describe the evolution of this field and, with a focus on thrombogenic effectors, summarize the current literature with respect to emerging trends in “coaguligand” development, in targeted tumor vessel destruction, and in expansion of the approach to the treatment of brain vascular malformations.


  • Targeting of externalized αB-crystallin on irradiated endothelial cells with pro-thrombotic vascular targeting agents: Potential applications for brain arteriovenous malformations

    by Sinduja Subramanian, Zhenjun Zhao, Fahimeh Faqihi, Georges E. Grau, Valery Combes, David W. Inglis, Vaughan Moutrie, Marcus A. Stoodley, Lucinda S. McRobb